Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux–Lamy syndrome): under-recognized and challenging to diagnose
- 2.6k Downloads
Mucopolysaccharidosis IVA (MPS IVA, or Morquio A syndrome) and VI (MPS VI, or Maroteaux–Lamy syndrome) are autosomal recessive lysosomal storage disorders. Skeletal abnormalities are common initial presenting symptoms and, when recognized early, may facilitate timely diagnosis and intervention, leading to improved patient outcomes. Patients with slowly progressing disease and nonclassic phenotypes can be particularly challenging to diagnose. The objective was to describe the radiographic features of patients with a delayed diagnosis of MPS IVA or VI.
Materials and Methods
This was a retrospective study. The records of 5 MPS IVA and 3 MPS VI patients with delayed diagnosis were reviewed. Radiographs were evaluated by a radiologist with special expertise in skeletal dysplasias.
An important common theme in these cases was the appearance of multiple epiphyseal dysplasia (MED) with epiphyseal changes seemingly confined to the capital (proximal) femoral epiphyses. Very few patients had the skeletal features of classical dysostosis multiplex.
Radiologists should appreciate the wide phenotypic variability of MPS IVA and VI. The cases presented here illustrate the importance of considering MPS in the differential diagnosis of certain skeletal dysplasias/disorders, including MED, some forms of spondylo-epiphyseal dysplasia (SED), and bilateral Perthes-like disease. It is important to combine radiographic findings with clinical information to facilitate early testing and accurate diagnosis.
KeywordsMucopolysaccharidosis MPS Morquio Morquio A Maroteaux-Lamy MPS IVA MPS VI Dysostosis multiplex Multiple epiphyseal dysplasia MED Spondylo-epiphyseal dysplasia SED
The mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by defects in glycosaminoglycan (GAG) catabolism  and are classified under the dysostosis multiplex group of skeletal dysplasias . The recent emergence of specific therapies for some of the MPS disorders has brought to the forefront the importance of accurate and early diagnosis as a means of improving patient outcomes . However, limited disease awareness and extensive clinical heterogeneity contribute to delays in the diagnosis of these rare disorders. Many radiographic and clinical manifestations of MPS may mimic those of other skeletal dysplasias, further complicating the path to diagnosis. Moreover, once clinical suspicion has been established, limitations and complications associated with diagnostic assays may delay definitive confirmation [4, 5].
In this paper, we present 8 cases that highlight the challenges associated with diagnosing MPS IVA (Morquio A syndrome) and MPS VI (Maroteaux–Lamy syndrome), two MPS disorders for which enzyme replacement therapy (ERT) is available or in development [6, 7]. MPS IVA is an autosomal recessive condition resulting from insufficient activity of N-acetylgalactosamine-6-sulfatase (GALNS), an enzyme that degrades keratan sulfate and chondroitin-6-sulfate . MPS VI is an autosomal recessive disorder caused by deficient activity of N-acetylgalactosamine 4-sulfatase (arylsulfatase B or ARSB), the enzyme that catabolizes dermatan sulfate . Classic signs and symptoms include short stature, skeletal abnormalities with some of the characteristic radiographic changes of dysostosis multiplex, joint problems, respiratory complications, cardiac disease, ocular abnormalities, and hearing loss [8, 9, 10, 11]. The onset of symptoms usually occurs within the first 2 years of life in severely affected patients. In contrast, individuals with more slowly progressive disease typically develop symptoms later in life and may present with more subtle disease manifestations, increasing the likelihood of a delayed or missed diagnosis [12, 13, 14, 15]. Many MPS IVA and VI individuals are at risk of multisystem impairment and significant morbidity, underscoring the importance of early diagnosis and multidisciplinary management, regardless of phenotype [8, 10, 16, 17]. By recognizing the radiographic abnormalities associated with these disorders, the radiologist can play a critical role in facilitating timely testing, diagnosis, and intervention. With the aim of improving radiologists’ recognition of possible MPS disease across a broad spectrum of presentations and beyond the classic phenotypes, we reviewed the radiographs and clinical information of 8 patients who were initially diagnosed with or suspected of having other skeletal disorders, and discuss the radiographic findings that might generate suspicion of MPS.
Materials and methods
We reviewed the medical records of 5 MPS IVA and 3 MPS VI patients with delayed diagnosis. Radiographs were retrospectively reviewed by a pediatric radiologist (R.S. Lachman) with special expertise in skeletal dysplasias. In addition, confirmed cases of MPS in the radiographic database of the International Skeletal Dysplasia Registry were analyzed to determine the referring and actual diagnoses.
Patient 1, a Caucasian female, presented with mid-thoracic back pain and scoliosis at age 9 years. Her height was 131.2 cm (25th percentile) and her weight was 25.3 kg (10th percentile). Radiographs were interpreted as revealing L1 hemivertebra, generalized platyspondyly, and mild epiphyseal dysplasia. Cardiac abnormalities (mitral and triscuspid prolapse), joint laxity, and a barrel-shaped chest were also noted. Urinary GAG excretion was normal and a diagnosis of spondylo-epiphyseal dysplasia tarda (SEDT) was made. Kyphoscoliosis continued to progress. By age 21 years, she had severe bilateral hip pain; her height at this time was 151 cm (<5th percentile). Between ages 23 and 24 years, both hips were replaced. Corneal dystrophy (pre-Descemet’s dystrophy) was noted at age 25. Vocal cord nodules were removed at age 27. The patient returned to genetics at age 29 to discuss the potential risks to future offspring. A repeat urinary GAG screen did not reveal abnormalities. However, a review and discussion of this case with a metabolic specialist prompted enzymatic activity testing for and subsequent diagnosis of MPS IVA.
The final diagnosis was MPS IVA.
Patient 2, a Caucasian girl, was noted to have an abnormal gait during a routine pediatric examination at age 4. Her height and weight at age 5 years were 109 cm (9th percentile) and 20 kg (52nd percentile) respectively. At age 6, the patient was admitted to a pediatric hospital for diagnostic evaluation due to gait abnormalities, weakness, and motor developmental delay. An MRI of the hips was interpreted as normal and excluded Legg–Calvé–Perthes disease (Perthes disease). Clinical evaluations including echocardiography were normal. At age 7 years she was seen by an orthopedic surgeon. Radiographs and an MRI of the spine showed “protrusion of L2,” while re-evaluation of the hip MRI and a hip radiograph revealed bilateral flattening of the epiphyses of the femoral heads. She was diagnosed with MED. A second orthopedic surgeon suspected SED because of some involvement of the spine and a genetics evaluation was recommended. Suspicion of MPS IVA prompted diagnostic testing for lysosomal storage disorders. Urinary GAG excretion was normal, but reduced GALNS activity led to a diagnosis of MPS IVA at age 8. Her height at diagnosis was 119.5 cm (3rd percentile).
The final diagnosis was MPS IVA.
Patient 3, a Korean male, first presented with hip pain at age 11 years, and bilateral Perthes-like disease was suspected. Aggravated hip pain led him to see an orthopedic surgeon at age 27 years. He is of average stature for an adult Korean male, with a height of 169 cm and a weight of 74 kg. Radiographic abnormalities of the spine, pelvis/hips, and knees led to suspected X-linked SEDT, but this was not confirmed by mutation analysis of SEDL (TRAPPC2). Molecular testing for SEDC (COL2A1) and MED (COMP, MATN3, COL9A1-3) did not reveal any deleterious mutations either. Whole exome sequencing identified two GALNS mutations, c.317A>G (p.N106S) and c.553delG (p.E185Rfx14), which were confirmed by Sanger sequencing. These mutations have not been previously reported among individuals with MPS IVA or any other disease. The patient is a compound heterozygote for these two mutations. Reduced GALNS activity confirmed a diagnosis of MPS IVA.
The final diagnosis was MPS IVA.
Patient 4, a 2 ½ -year-old Caucasian girl with “congenital kyphosis”, was seen by orthopedics because of parental concerns about prominent hardware, a waddling gait, and reduced mobility. A genetics evaluation at age 3½ years revealed a height of 96.5 cm (29th percentile). Proximal femoral epiphyseal flattening was detected on radiographs and a type II collagenopathy was considered; however, the mutation analysis was not consistent with a type II collagenopathy. At age 9, her height was 116.5 cm (< 3rd percentile). Mitral valve thickening, mild tricuspid insufficiency, and restrictive lung disease were observed. Slightly elevated urinary GAG levels prompted enzyme activity analysis. She was diagnosed with MPS IVA based on reduced GALNS activity. She is a compound heterozygote for two known GALNS missense mutations, c.776G>A (p.R259Q) and c.901G>T (p.G301C) .1
The final diagnosis was MPS IVA.
Patient 5 is a physically active Caucasian boy who started limping at age 4 years and started experiencing knee pain at age 5 years. He was diagnosed with bilateral Perthes disease at age 7. He presented to the skeletal dysplasia clinic at age 9 years, when his height was 125.2 cm (5.5th percentile) and his weight was 27.1 kg (30th percentile). Mild scoliosis was the only abnormality noted on physical examination. Two urinary GAG screens were normal. SEDC, Stickler syndrome, and X-linked SEDT were considered, but not confirmed by molecular testing. After 1 year, he returned to the clinic with a developing chest wall deformity and increasing hip pain. Reduced GALNS activity led to a diagnosis of MPS IVA. One copy of the c.901G>T (p.G301C) mutation on the GALNS gene was identified .2
The final diagnosis was MPS IVA.
Patient 6, a Caucasian girl, was referred to orthopedics at age 6 years because of mildly short stature, an abnormal gait, and toe-walking. Her height at the time was 110 cm (10th percentile). At age 7, a diagnosis of spondylo-epiphyseal dysplasia congenita (SEDC) was established based on apparent radiographic abnormalities of the pelvis and spine. Snoring and a history of frequent ear infections prompted referral to an ear/nose/throat (ENT) specialist, and she underwent tonsillectomy and adenoidectomy at age 7. She was diagnosed with hearing loss and chronic otitis media at age 9. During recurrence risk counseling for SEDC, a geneticist clinically suspected MPS based on a photograph of the patient (coarse facial features). Enzyme activity testing at age 10 established a diagnosis of MPS VI.
The final diagnosis was MPS VI.
Patient 7 is a girl of Asian origin who was seen by orthopedics at 9 years of age because of short stature. Her radiographs were interpreted as showing bilateral acetabular dysplasia with coxa magna, deformities of the femoral heads, and epiphyseal and metaphyseal abnormalities. Corneal clouding was noted, therefore the possibility of MPS was raised and the patient was referred to genetics. Physical examination revealed a height of 117.5 cm (<5th percentile), weight of 22.0 kg (5th percentile), and head circumference of 54.5 cm (+1 SD). Some limitation of range of motion of the shoulder was noted. A second review of her radiographs led to an initial impression of MED and referral to a skeletal dysplasia clinic. Bilateral corneal opacities were observed upon ophthalmological examination. At age 10 years, a heart murmur was detected. Subsequent cardiology assessments revealed mitral valve thickening, mitral valve prolapse, mild mitral regurgitation, and mild aortic insufficiency. At a follow-up genetics visit, mild valgus deformity of the knees, a waddling gait, lordosis of the spine, and a broad flat nasal bridge were noted. Review of the patient’s history and symptoms led to suspicion of an MPS disorder and prompted diagnostic testing for lysosomal storage disorders and a full skeletal survey. MPS VI was diagnosed based on low ARSB activity in leukocytes.
The final diagnosis was MPS VI.
Patient 8, a Caucasian boy, was diagnosed with bilateral Perthes-like disease, but was referred to genetics at age 10 years for possible skeletal dysplasia. On physical examination his height was 143 cm (65th percentile), his weight was 43.5 kg (92th percentile), and head circumference was 56.2 cm (95th percentile). He was noted to have mild scoliosis, a protuberant abdomen, thickened gums, and hyperreflexia at his knees and ankles. Radiographs were interpreted to reveal symmetrical epiphyseal abnormalities of the proximal femurs and irregularities of one vertebral endplate. His urinary GAG screen was normal; however, a trace amount of dermatan sulfate was observed. Molecular testing of the COL2A1 gene and the COL11A2 gene did not reveal any deleterious mutations that would diagnose SEDC and Stickler dysplasia respectively. At age 12 years, the patient returned to clinic with continuing hip pain. Repeat screening for MPS revealed mildly elevated urinary GAG excretion as well as trace levels of dermatan sulfate, prompting enzyme activity analysis for MPS VI. Low ARSB activity and subsequent molecular testing confirmed a diagnosis of MPS VI. This patient is homozygous for the c.629A>G (p.Y210C) missense mutation in the ARSB gene .3
The final diagnosis was MPS VI.
Taken together, all of these cases demonstrate that MPS disease may often be radiographically confused with other skeletal dysplasias/entities, in particular MED, SED, and bilateral Perthes-like disease.
International Skeletal Dysplasia Registry database search
A search in the International Skeletal Dysplasia Registry reveals that of the total 151 cases of confirmed dysostosis multiplex submitted for evaluation, approximately 75 % of referring physicians did not recognize the likelihood that their case clinically/radiologically represented a form of MPS disease. MED, SEDC, Dyggve–Melchior–Clausen dysplasia including Smith–McCort syndrome, and pseudo-achondroplasia were among the most common referring diagnoses.
Diagnosing MPS IVA or VI can be a challenging and protracted process, as illustrated by the cases described here. An accurate diagnosis typically requires recognition of specific clinical and/or radiographic signs and symptoms combined with laboratory confirmation, which often involves multidisciplinary input. Delayed or incorrect diagnosis can result from a number of factors including the incorrect interpretation of radiographs, lack of disease awareness, wide phenotypic variability, phenotypic overlap with other disorders, and limitations of urinary GAG screening. The radiologist can play a critical role in ensuring that an accurate diagnosis is reached expeditiously by raising suspicion of an MPS disorder if dysostosis multiplex changes are evident. However, our retrospective study reveals a significant finding: MPS disease can radiographically manifest as an apparent type of MED with isolated dysplastic CFE (MED Ribbing type) with very few, if any, additional findings suggestive of classical dysostosis multiplex. MED Ribbing type is characterized by epiphyseal ossification delay and dysplastic-appearing epiphyses, usually by definition confined to the hips .
The manifestations of dysostosis multiplex
Dysostosis multiplex manifestations
Abnormal J-shaped sella turcica
Thickened diploic space
Short, thick clavicles
Several superiorly notched (inferiorly beaked) vertebral bodies
Posterior scalloping of vertebrae
Middle beaked vertebral bodies (common in MPS IVA)
Rounded iliac wings
Inferior tapered ilia
Mildly hypoplastic epiphyses (often generalized)
Hypoplastic, dysplastic, or fragmented CFE
Proximal humeral notching
Long narrow femoral necks
Hypoplastic distal ulnae
Thick short diaphyses
Proximally pointed metacarpals
Short broad metacarpals with thin cortices
Irregular/hypoplastic carpal bones
Tarsal bones with irregular contours
Conducting a full skeletal survey is mandatory if an MPS or other skeletal dysplasia is suspected; imaging only one or a few regions is likely to result in missed findings and may lead to a delayed or incorrect diagnosis. It is also important to note that some changes of dysostosis multiplex, such as proximal pointing of the metacarpals, vertebral body changes, and lower ileal changes, may become impossible to detect after the time of epiphyseal plate fusion. For patients who may not present with apparent clinical symptoms until late childhood or adulthood, review of early or pre-pubertal radiographs can be quite helpful if they are available.
If an MPS disorder or other skeletal dysplasia is suspected, a comprehensive examination that includes clinical findings must be conducted, which requires collaboration between the radiologist, referring clinician, and the clinical geneticist. Extra-skeletal manifestations, including corneal clouding, specific cardiac abnormalities, and facial dysmorphology, can provide vital clues for achieving a correct diagnosis of MPS, but are often overlooked or missed due to a lack of disease awareness, as demonstrated by several of our cases.
Diagnostic enzyme testing is required for the definitive diagnosis of MPS IVA or VI [4, 5]. Urinary GAG analysis alone is unreliable and can be misleading, as illustrated by several of the cases. Molecular analysis can be useful in diagnosing or confirming a diagnosis of an MPS disorder. Unless two known pathogenic gene mutations have been identified on separate alleles, enzyme activity testing should always be used to confirm a diagnosis of MPS IVA or VI. If molecular testing is not performed to confirm enzyme activity results, it is important to measure the activity of a second sulfatase enzyme to exclude multiple sulfatase deficiency [4, 5]; additionally, for suspected MPS IVA, it is highly recommended to also measure β-galactosidase activity to rule out MPS IVB . Accurate diagnosis requires corroboration of complete radiographic and clinical information with the laboratory findings. Once diagnosed, MPS IVA and VI patients should receive multidisciplinary care and can be considered for ERT or other therapeutic intervention if such treatment modalities are available.
While recognition of dysostosis multiplex changes can facilitate the timely diagnosis of MPS disease, our study indicates that MPS IVA and VI can manifest radiographically as MED with isolated dysplastic CFE (MED Ribbing type), with very few, if any, additional findings to suggest dysostosis multiplex. The cases presented here illustrate the wide phenotypic variability of these disorders, underscore the importance of considering MPS in the differential diagnosis of certain skeletal dysplasias/disorders, particularly MED, SED, and bilateral Perthes-like disease, and emphasize the need to combine radiographic, clinical, biochemical and molecular findings to achieve an accurate diagnosis.
S. Ikegawa is supported by research grants for exome sequencing from the Japanese Ministry of Health, Labor and Welfare (23300101 and 23300201).
Conflicts of interest
R.S. Lachman and L.A. Clarke have provided consulting services to BioMarin Pharmaceutical Inc (BioMarin). B.K. Burton has received honoraria, consulting fees, and funding for clinical trials from BioMarin, and is an investigator in MPS IVA clinical trials. C. Lampe has received honoraria, speaker fees, unrestricted research grants, and travel support from BioMarin. N.J. Mendelsohn has received honoraria, research grants, and travel support from BioMarin, and is an investigator in MPS IVA clinical trials. P. Tanpaiboon has received honoraria and travel support from BioMarin and is an investigator in MPS IVA clinical trials. R. Shediac is an employee and shareholder of BioMarin. K.K. White has received honoraria, research grants, and travel support from BioMarin, and is an investigator in MPS IVA clinical trials. S. Hoffinger, S. Ikegawa, D.-K. Jin, H. Kano, and O.-H. Kim declare that they have no conflicts of interest.
- 7.Hendriksz C, Burton BK, Fleming T, Giugliani R, Harmatz P, Hughes D, et al. A multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BMN 110 treatment for mucopolysaccharidosis IVA (Morquio syndrome type A). Mol Genet Metab. 2013;108(2):S48.CrossRefGoogle Scholar
- 16.Hendriksz C. Improved diagnostic procedures in attenuated mucopolysaccharidosis. Br J Hosp Med (Lond). 2011;72(2):91–5.Google Scholar
- 18.Mendelsohn NJ, Wood T, Olson RA, Temme R, Hale S, Zhang H, et al. Spondyloepiphyseal dysplasias and bilateral Legg-Calve-Perthes disease: diagnostic considerations for mucopolysaccharidoses. JIMD Rep. 2013;11:125–32.Google Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.